

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



VENTUREPHARM LABORATORIES LIMITED

萬全科技藥業有限公司*

(incorporated in the Cayman Islands with limited liability)

(Stock code: 8225)

**POSTPONEMENT OF BOARD MEETING
DELAY IN PUBLICATION OF ANNOUNCEMENT FOR THE 2013 ANNUAL RESULTS
AND THE 2014 FIRST QUARTERLY RESULTS**

The Board (the “**Board**”) of directors (the “**Directors**”) of Venturepharm Laboratories Limited (the “**Company**”) refers to the announcements dated 24 June 2014, 12 June 2014, 14 May 2014, 28 March 2014 and 20 March 2014 to convene a Board meeting for the purpose of considering and approving, among other matters, the audited consolidated financial results of the Company and its subsidiaries for the year ended 31 December 2013 (the “**2013 Annual Results**”) and for the three months ended 31 March 2014 (the “**2014 First Quarterly Results**”) and the draft announcements in respect of the results to be published on the GEM website.

The Board wishes to inform the Shareholders that as additional time is required for the Company to prepare the information requested and for the auditors of the Company to perform and complete the audit of 2013 Annual Results, the Board meeting originally scheduled to be held on 16 July 2014 will be postponed to 29 July 2014 and the publication of announcement for the 2013 Annual Results and the 2014 First Quarterly Results will be postponed to 29 July 2014.

Main agenda of the Board meeting include but not limited to the following:

- 1 To consider and approve the 2013 Annual Results;
- 2 To consider and approve the 2014 First Quarterly Results;
- 3 To consider and approve the Convertible Notes Agreement; and
- 4 To propose convening an extraordinary shareholders’ meeting.

At the request of the Company, trading in the securities of the Company on the Stock Exchange was suspended since 9:00 a.m. on 1 April 2014, and will remain suspended until the release of an announcement relating to the publication of 2013 Annual Results and 2014 First Quarterly Results.

By order of the Board
Venturepharm Laboratories Limited
William Xia Guo
Chairman

Beijing, PRC, 15 July 2014

** For identification purpose only*

As at the date of this announcement, the Board comprises two executive directors, being Mr. William Xia Guo and Dr. Maria Xue Mei Song; three non-executive directors, being Mr. Feng Tao, Dr. Nathan Xin Zhang and Mr. Li Jin Liang; and three independent non-executive directors, being Dr. Zhang Jing An, Mr. Paul Contomichalos and Dr. Wu Shou Yuan.

This announcement, for which the directors of the Company (the “Directors”) collectively and individually accept responsibility, includes particulars given in compliance with the Rules Governing the Listing of securities of the Growth Enterprise Market of the Stock Exchange for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, conform that, to the best of their knowledge and belief: (1) the information contained in this announcement is accurate and complete in all material respect and not misleading; (2) there are no other matters the omission of which would make any statement in all material respects and not misleading; and (3) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.

This announcement will remain on the GEM website with the domain name of www.hkgem.com on the “Latest Company Announcements” page for at least 7days from the date of its posting and on the Company’s website at www.venturepharm.com